中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
5期
546-549
,共4页
巨细胞病毒性肝炎%更昔洛韦%门冬氨酸鸟氨酸%婴儿
巨細胞病毒性肝炎%更昔洛韋%門鼕氨痠鳥氨痠%嬰兒
거세포병독성간염%경석락위%문동안산조안산%영인
Cytomegalovirus hepatitis%Ganciclovir%L-ornithine-L-aspartate%Infant
目的 探讨更昔洛韦联合门冬氨酸鸟氨酸对婴儿巨细胞病毒(CMV)性肝炎的疗效及副作用.方法 我院于2009年12月至2010年12月住院60例婴儿CMV性肝炎患儿,给予更昔洛韦联合门冬氨酸鸟氨酸治疗,观察治疗前、后血清总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、碱性磷酸酶(AKP)及肝、脾回缩情况,并观察药物不良反应.结果 更昔洛韦联合门冬氨酸鸟氨酸治疗后血清TBIL、ALT下降,肝、脾回缩,与治疗前比较差异均有统计学意义[治疗前、后血清TBIL浓度:(158.32±15.64)、(60.73±16.46)μmol/L,t=5.74,P＜0.05; ALT:( 132.85±32.14)、(75.81±27.63) U/L,t=2.92,P＜0.05；肝脏回缩:(4.16±0.53)、(2.35 ±0.41) cm,t =8.27,P＜0.05；脾脏回缩:(1.64±0.21)、(1.03±0.19)cm,t =5.03 P ＜0.05].更昔洛韦治疗有肝功能损害以及皮疹的不良反应,门冬氨酸鸟氨酸有呕吐等轻微胃肠反应.结论更昔洛韦联合门冬氨酸鸟氨酸治疗CMV性肝炎疗效好,但应注意监测不良反应的发生.
目的 探討更昔洛韋聯閤門鼕氨痠鳥氨痠對嬰兒巨細胞病毒(CMV)性肝炎的療效及副作用.方法 我院于2009年12月至2010年12月住院60例嬰兒CMV性肝炎患兒,給予更昔洛韋聯閤門鼕氨痠鳥氨痠治療,觀察治療前、後血清總膽紅素(TBIL)、丙氨痠氨基轉移酶(ALT)、堿性燐痠酶(AKP)及肝、脾迴縮情況,併觀察藥物不良反應.結果 更昔洛韋聯閤門鼕氨痠鳥氨痠治療後血清TBIL、ALT下降,肝、脾迴縮,與治療前比較差異均有統計學意義[治療前、後血清TBIL濃度:(158.32±15.64)、(60.73±16.46)μmol/L,t=5.74,P＜0.05; ALT:( 132.85±32.14)、(75.81±27.63) U/L,t=2.92,P＜0.05；肝髒迴縮:(4.16±0.53)、(2.35 ±0.41) cm,t =8.27,P＜0.05；脾髒迴縮:(1.64±0.21)、(1.03±0.19)cm,t =5.03 P ＜0.05].更昔洛韋治療有肝功能損害以及皮疹的不良反應,門鼕氨痠鳥氨痠有嘔吐等輕微胃腸反應.結論更昔洛韋聯閤門鼕氨痠鳥氨痠治療CMV性肝炎療效好,但應註意鑑測不良反應的髮生.
목적 탐토경석락위연합문동안산조안산대영인거세포병독(CMV)성간염적료효급부작용.방법 아원우2009년12월지2010년12월주원60례영인CMV성간염환인,급여경석락위연합문동안산조안산치료,관찰치료전、후혈청총담홍소(TBIL)、병안산안기전이매(ALT)、감성린산매(AKP)급간、비회축정황,병관찰약물불량반응.결과 경석락위연합문동안산조안산치료후혈청TBIL、ALT하강,간、비회축,여치료전비교차이균유통계학의의[치료전、후혈청TBIL농도:(158.32±15.64)、(60.73±16.46)μmol/L,t=5.74,P＜0.05; ALT:( 132.85±32.14)、(75.81±27.63) U/L,t=2.92,P＜0.05；간장회축:(4.16±0.53)、(2.35 ±0.41) cm,t =8.27,P＜0.05；비장회축:(1.64±0.21)、(1.03±0.19)cm,t =5.03 P ＜0.05].경석락위치료유간공능손해이급피진적불량반응,문동안산조안산유구토등경미위장반응.결론경석락위연합문동안산조안산치료CMV성간염료효호,단응주의감측불량반응적발생.
Objective To study the efficacy and side effects of Ganciclovir combined with L-ornithine-L-aspartate on infant cytomegalovirus(CMV) hepatitis.Methods Sixty infants with CMV hepatitis hospitalized in our hospital from Dec.2009 to Dec.2010 were treated with ganciclovir combined with L-ornithine-L- aspartate.The parameters observed in the study included the pre-and post-treatment data on total Bilirubin (TBIL),alanine aminotransferase (ALT),alkaline Phosphatase (AKP)and the retraction of liver and spleen,as well as the adverse reactions of the treatment.Results The treatment significantly decreased serum TBIL (t =5.74,P ＜ 0.05 ),ALT( t =2.92,P ＜ 0.05 ) and liver( t =8.27 P ＜ 0.05 ) and spleen volume ( t =5.03,P ＜0.05).However,side effects such as liver damage and rash occurred occasionally during the ganciclovir treatment.Intravenous infusion of L-omithine-L-aspartate caused side effects such as vomiting and other mild gastrointestinal reactions.Conclusion The treatment of Ganciclovir combined with L-ornithine-L-aspartate on infant cytomegalovirus hepatitis created good efficacy and can be considered as the first treatment choice.Though it is relatively safe,adverse reactions should be monitored during the treatment.
